BRCA1 and breast cancer: The identification of valid biomarkers that predict the response to PARPi and methods to overcome resistance to PARP inhibitors will improve the therapeutic spectrum of these agents, introducing them as an efficient therapeutic option in locally advanced and metastatic BC with germline BRCA1/2 mutations.